Suprarenal Abdominal Aortic Aneurysm Research Articles

Current Medicare reimbursement for complex endovascular aortic repair is inadequate based on results from a multi-institutional cost analysis

ObjectiveComplex endovascular juxta-, para- and suprarenal abdominal aortic aneurysm repair (comEVAR) is frequently accomplished with commercially available fenestrated (FEVAR) devices or off-label use of aortoiliac devices with parallel branch stents (chEVAR). We sought to evaluate the implantable vascular device costs incurred with these procedures as compared with standard Medicare reimbursement to determine the financial viability of comEVAR in the modern era. MethodsFive geographically distinct institutions with high-volume, complex aortic centers were included. Implantable aortoiliac and branch stent device cost data from 25 consecutive, recent, comEVAR in the treatment of juxta-, para-, and suprarenal aortic aneurysms at each center were analyzed. Cases of rupture, thoracic aneurysms, reinterventions, and physician-modified EVAR were excluded, as were ancillary costs from nonimplantable equipment. Data from all institutions were combined and stratified into an overall cost group and two, individual cost groups: FEVAR or chEVAR. These groups were compared, and each respective group was then compared with weighted Medicare reimbursement for Diagnosis-Related Group codes 268/269. Median device costs were obtained from an independent purchasing consortium of >3000 medical centers, yielding true median cost-to-institution data rather than speculative, administrative projections or estimates. ResultsA total of 125 cases were analyzed: 70 FEVAR and 53 chEVAR. Two cases of combined FEVAR/chEVAR were included in total cost analysis, but excluded from direct FEVAR vs chEVAR comparison. Median Medicare reimbursement was calculated as $35,755 per case. Combined average implantable device cost for all analyzed cases was $28,470 per case, or 80% of the median reimbursement ($28,470/$35,755). Average FEVAR device cost per case ($26,499) was significantly lower than average chEVAR cost per case ($32,122; P < .002). Device cost was 74% ($26,499/$35,755) of total reimbursement for FEVAR and 90% ($32,122/$35,755) for chEVAR. ConclusionsResults from this multi-institutional analysis show that implantable device cost alone represents the vast majority of weighted total Medicare reimbursement per case with comEVAR, and that chEVAR is significantly more costly than FEVAR. Inadequate Medicare reimbursement for these cases puts high-volume, high-complexity aortic centers at a distinct financial disadvantage. In the interest of optimizing patient care, these data suggest a reconsideration of previously established, outdated, Diagnosis-Related Group coding and Medicare reimbursement for comEVAR.

Vascular graft infection with duodenal fistulization 10 years after hybrid endovascular aortic repair with renovisceral debranching: a case report

BackgroundA secondary aortoenteric fistula after an aortic graft replacement or endovascular aortic repair is a rare but devastating complication that leads to extremely high morbidity and mortality. Because reports of vascular graft infection with enteric fistulization complicating in a hybrid aortic repair with renovisceral debranching are limited, the management method such as the extent of removal of the infected graft, reconstruction procedures, and the ideal type of graft are still debatable.Case presentationWe report a successful case of a 73-year-old man presenting a vascular graft infection with duodenal fistulization, 10 years after hybrid endovascular aortic repair with renovisceral debranching for a 60-mm diameter of supra-renal abdominal aortic aneurysm. The patient had a history of polymyalgia rheumatica on oral prednisolone, perigraft seroma, deep vein thrombosis, and an allergy to rifampicin. The patient eventually recovered after partial removal of the grafts, in situ reconstruction using Fusion Bioline vascular prosthesis, primary duodenal repair, application of omental flap, and antibiotics without any evidence of re-infection after 1.5 years.ConclusionsAlthough hybrid endovascular aortic repair is considered advantageous, especially for the elderly and high-risk patients, due to the avoidance of extracorporeal circulation and thoracotomy; once a devastating complication happens, an optimal treatment method should be considered for patients with several comorbidities. Although our procedures provided favorable results, careful monitoring to avoid re-infection is mandatory.

O029 Adverse renal outcomes following endovascular or open repair of infra-renal and supra-renal abdominal aortic aneurysms: a systematic review and meta-analysis

Abstract Introduction This study aims to quantify the risk of permanent renal dialysis for AAA repair, with comparison between endovascular (EVAR) and open repair (OAR) techniques for suprarenal (SR) and infrarenal (IR) AAA. Methods Systematic review, meta-analysis and meta-regression of post-operative, permanent dialysis outcomes were performed, following PRISMA guidance (Prospero registration: CRD42021272422). Database searches were conducted on MEDLINE, Embase, CENTRAL using ProQuest Dialog. We included data published after 2011, reporting primary elective AAA repair, for a minimum of 100 patients with &amp;gt;75% of operations undertaken after January 1, 2000. Results Seventy-nine studies (IR AAAs: 54877 EVAR &amp; 7145; SR AAAs: 4241 EVAR &amp; 1723 OAR) were included (n=67986). Overall, low rates of permanent dialysis were reported: 0.35% of IR-EVAR, 0.68% IR-OAR, 0.82% SR-EVAR, and 0.59% SR-OAR. No significant difference in the risk of permanent dialysis for endovascular and open repair was observed (EVAR vs. OAR: odds ratio (OR) 0.52 95% CI[.06, 4.78], for IR, 2.14 [.46, 10.05], for SR). A lower risk of permanent dialysis was observed for IR vs. SR EVAR (OR .05 [0, .46]). Meta-regression indicated that post-operative permanent dialysis decreased over time as determined by study midpoint for IR-EVAR and IR-OAR. For IR-OAR, increased dialysis rates were significantly associated with study participants’ ages. Conclusion The rate of permanent dialysis &amp;lt;1% for all modalities of SR and IR AAA repair. For EVAR, the risk of dialysis was higher for SR compared to IR AAA. The likelihood of permanent dialysis has decreased with modern practice yet increases among older patients.

Long-Term Survival and Quality of Life After Fenestrated Endovascular Repair for Complex Abdominal Aortic Aneurysms.

Fenestrated endovascular repair (FEVAR) has become a widely used treatment option for complex abdominal aortic aneurysms (AAA) but long-term survival and quality of life (QoL) outcomes are scarce. This single center cohort study aims to evaluate both long-term survival and QoL after FEVAR. All juxtarenal and suprarenal AAA patients treated with FEVAR in a single-center between 2002 and 2016 were included. QoL scores, measured by the RAND 36-Item Short Form Survey (SF-36), were compared with baseline data of the SF-36 provided by RAND. A total of 172 patients were included at a median follow-up of 5.9years (IQR 3.0-8.8). Follow-up at 5 and 10years post-FEVAR yielded survival rates of 59.9% and 18%, respectively. Younger patient age at surgery had a positive influence on 10-year survival and most patients died due to cardiovascular pathology. Emotional well-being was better in the research group as compared to baseline RAND SF-36 1.0 data (79.2 ± 12.4 vs 70.4 ± 22.0; P < 0.001). Physical functioning (50 (IQR 30-85) vs 70.6 ± 27.4; P = 0.007) and health change (51.6 ± 17.0 vs 59.1 ± 23.1; P = 0.020) were worse in the research group as compared to reference values. Long-term survival was 60% at 5-years follow-up, which is lower than reported in recent literature. An adjusted positive influence of younger age at surgery was found on long-term survival. This could have consequences for future treatment indication in complex AAA surgery but further large-scale validation is necessary.

Current Medicare Reimbursement for Complex Endovascular Aortic Repair Is Inadequate Based on Results From a Multi-institutional Cost Analysis

Complex endovascular juxta-, para-, and suprarenal abdominal aortic aneurysm repair (com-EVAR) is frequently accomplished with commercially available fenestrated (FEN) devices or off-label use of aortoiliac devices with parallel branch stents (chEVAR). We sought to evaluate the implantable vascular device costs incurred with these procedures as compared with standard Medicare reimbursement to determine the financial viability of com-EVAR in the modern era.

Infrarenal Remains Infrarenal-EVAR Suitability of Small AAA Is Rarely Compromised despite Morphological Changes during Surveillance.

The aim was to analyze small abdominal aortic aneurysm (AAA) morphology during surveillance with regard to standard endovascular aortic repair (EVAR) suitability. This retrospective single-center study included all patients (n = 52, 48 male, 70 ± 8 years) with asymptomatic AAA ≤ 5.4 cm undergoing ≥2 computed tomography angiography(CTA)/magnetic resonance imaging (MRI) studies (interval: ≥6 months) between 2010 and 2018. Aneurysm diameter, neck quality (shape, length, angulation, thrombus/calcification), aneurysm thrombus, and distal landing zone diameters were compared between first and last CTA/MRI. Resulting treatment plan changes were determined. Neck shortening occurred in 25 AAA (mean rate: 2.0 ± 4.2 mm/year). Neck thrombus, present in 31 patients initially, increased in 16. Average AAA diameters were 47.7 ± 9.3 mm and 56.3 ± 11.6 mm on first and last CTA/MRI, mean aneurysm growth rate was 4.2 mm/year. Aneurysm thrombus was present in 46 patients primarily, increasing in 32. Neck thrombus growth and neck length change, aneurysm thrombus amount and aneurysm growth and aneurysm growth and neck angulation were significantly correlated. A total of 46 (88%) patients underwent open (12/46) or endovascular (34/46) surgery. The planned procedure changed from EVAR to fenestrated EVAR in two patients and from double to triple fenestrated EVAR in one. Thus, standard EVAR suitability was predominantly maintained as the threshold diameter for surgery was reached despite morphological changes. Consecutively, a possibly different pathogenesis of infra- versus suprarenal AAA merits further investigation.

Impact of stent-graft complexity on mid-term results in fenestrated endovascular aortic repair of juxtarenal and suprarenal abdominal aortic aneurysms.

The impact of stent-graft complexity on clinical outcome after fenestrated endovascular aortic aneurysm repair (FEVAR) has been conflicting in the literature. The objective of this study was to compare mid-term results of stent-grafts with renal fenestrations alone with more complex stent-grafts including mesenteric fenestrations. A single center retrospective study was conducted on 154 patients, who underwent FEVAR from 2006 to 2020 at our institution. There were 54 (35.1%) patients in the renal FEVAR group and 100 (64.9%) patients in the complex FEVAR group. Median follow-up of the total group was 25 months (IQR 7-45). There were no significant differences in technical success and perioperative mortality. Intraoperative complications (4% vs. 18%, P=0.001), operative time (145 min vs. 191 min, P=0.001), radiation dose (119372 mGy*cm2 vs. 159573 mGy*cm2, P=0.004) and fluoroscopy time (39 min vs. 54 min, P=0.007) were significantly lower in the renal FEVAR group. During follow-up target vessel instability, endoleaks and reinterventions were not significantly different between the two groups. In this single center retrospective study, renal FEVAR was a safe and effective treatment for patients with juxtarenal AAA demonstrating fewer intraoperative complications and similar mid-term outcomes as complex FEVAR. If the anatomy is compatible for renal FEVAR, it might be unnecessary to expose patients to potentially more complications by choosing a complex FEVAR strategy.

Retroperitoneal approach for suprarenal abdominal aortic aneurysm in Marfan syndrome

Cardiovascular Surgery and Interventions publishes original articles on topics in cardiovascular surgery, cardiovascular anesthesia and cardiology. These encompass all relevant clinical, surgical and laboratory studies, editorials, current and collective reviews, technical know-how papers, case reports, interesting images, “How to Do It” papers, correspondence and commentary.

Efficacy of point-of-care thromboelastography 6s to evaluate platelet function in a patient with pseudothrombocytopenia undergoing cardiopulmonary bypass: a case report

BackgroundPseudothrombocytopenia is a phenomenon caused by in vitro platelet aggregation induced by anticoagulants contained in blood sampling tubes. Thromboelastography (TEG) 6s is a common point-of-care viscoelastic test to assess intraoperative coagulation status, which may reduce the need for blood transfusions. The reliability and usefulness of TEG6s for patients with pseudothrombocytopenia has not been established.Case presentationWe present a patient with pseudothrombocytopenia, who underwent suprarenal abdominal aortic aneurysm repair under cardiopulmonary bypass. At the beginning of surgery, TEG6s with citrated blood sampling showed that the results were unaffected by the disease. After completion of the aortic repair and the administration of protamine, maximum amplitude of TEG6s and adequate hemostasis were achieved without platelet transfusions, while standard laboratory tests showed thrombocytopenia.ConclusionsIn the present patient who underwent cardiopulmonary bypass, TEG6s may have contributed to a reliable and useful assessment of coagulation and hemostatic status avoiding unnecessary platelet transfusions.

Type III endoleaks in complex endovascular abdominal aortic aneurysm repair within the Vascular Quality Initiative

ObjectiveType III endoleaks (T3ELs) following complex endovascular aneurysm repair (c-EVAR) for abdominal aortic aneurysm have been historically difficult to study due to their relative rarity. Previous studies within standard infrarenal EVAR have found an association between T3ELs and decreased survival. This study aims to evaluate the occurrence of T3ELs in a national multicenter cohort, identify potential procedural characteristics associated with T3EL development, and determine their impact on clinical outcomes in c-EVAR. MethodsA retrospective cohort review was conducted of elective c-EVAR for nonruptured aneurysms within the Vascular Quality Initiative (VQI) between January 2010 and March 2020. The VQI standards define c-EVAR as suprarenal or pararenal abdominal aortic aneurysms repaired with any thoracoabdominal repairs, fenestrated/branched repairs, parallel stent repairs, custom manufactured devices, and physician-modified endografts. End points assessed were rates of T3ELs within c-EVAR, and impact of T3ELs on reintervention and survival. Index endoleaks were defined as endoleaks discovered during index hospitalization. Incident endoleaks were defined as new endoleaks, which were not present at index hospitalization, discovered at follow-up. ResultsA total of 4070 c-EVAR cases were identified between January 2010 and March 2020, of which 2656 (65.2%) had appropriate follow-up data. One-half of the cohort had a modified or custom graft (n = 2055/4070; 50.5%). Branches were employed in 3687 patients (90.5%), whereas fenestrations and chimney techniques were documented in 13% (n = 533) and 15.1% (n = 613), respectively. The rate of index T3ELs was 4.1% (n = 167), and the rate of incident T3ELs at follow-up was 0.04% (n = 1). Devices categorized as either custom or physician-modified were utilized more frequently in patients with index T3ELs (78.4%; n = 131/167) compared with patients without index T3ELs (49.2%; n = 1924/3903) (P < .001). Compared with those without T3ELs, the presence of index T3ELs was not statistically associated with increased aortic reinterventions or increased mortality. ConclusionsT3ELs in c-EVAR remain relatively uncommon and are identified predominately at index hospitalization. Development of T3EL was associated with higher device modularity and modification, which suggests that as device technologies continue to advance and become more intricate, the occurrence of T3ELs may persist and continue to require evaluation. In this study, the presence of T3ELs did not appear to have a statistically significant relationship with aortic reinterventions or survival; however, these findings are not definitive due to low event rate numbers and high potential for type II errors. Amid the theoretical risk of device fatigue and degeneration, continued evaluations of large cohorts at extended follow-up intervals and diligent reporting remain paramount.

Initial Outcomes of Patients With Perirenal or Suprarenal Abdominal Aortic Aneurysms Treated in the chEVAS ONE Phase II Trial

The chimney endovascular aneurysm sealing (chEVAS) endograft uses parallel chimney grafting to the renal and visceral vessels with a Nellix EVAS system as an alternative endovascular repair of perirenal and suprarenal aortic aneurysms. The advantages of ChEVAS include a bilateral lower access profile (14F), off the shelf technology, and a potential reduction in the incidence of gutter leaks owing to the polymer filling of the aneurysm sac and aortic neck by the EVAS endobag. We report the early single-institution experience in using this novel technology as a part of the chEVAS ONE (chimney endovascular aneurysm sealing of new expanded indication) trial.

Evolution of Branch Vessel Incorporation During Emergent Endovascular Repair of Ruptured or Symptomatic Suprarenal and Thoracoabdominal Aortic Aneurysms

Emergent endovascular repair of suprarenal abdominal aortic aneurysms (SRAAAs) and thoracoabdominal aortic aneurysms (TAAAs) poses a significant challenge owing to obligatory branch vessel incorporation, time constraints, and lack of dedicated devices. At our regional aortic center, techniques to incorporate branch vessels during emergent repairs have included parallel grafting (PG), physician modified endografts (PMEGs), double-barrel/reversed iliac branch device (DB/rIBE), and in situ fenestration (ISF).

Mortality is High Following Elective Open Repair of Complex Abdominal Aortic Aneurysms

Objective To evaluate the 30 day mortality of elective open complex abdominal aortic aneurysm (cAAA) repair and identify factors associated with death. Methods This was a retrospective cohort study using a Targeted Vascular Module from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP). All patients undergoing elective repair for juxta- and suprarenal abdominal aortic aneurysm (AAA), or type IV thoraco-abdominal aneurysms (TAAA) from 2011 to 2017 were identified. Thirty day mortality and complication rates for open repair were established. A comparison endovascular aneurysm repair (EVAR) group was extracted from the same time period, and inverse probability weighting was applied for comparison. Logistic regression was used to identify factors independently associated with open repair mortality. Results Of the 957 patients who underwent an elective open cAAA repair over the study period, 65 (6.8%) died. The mean age of the patient was 71.3 ± 8.0 years. The distribution by aneurysm type was 605 juxtarenal AAA (28 deaths, 4.6%); 284 suprarenal AAA (16 deaths, 9.5%), and 68 type IV TAAA (10 deaths, 14.7%). During the same time period, there were 1149 endovascular repairs for cAAA, with 43 deaths (3.7%). After inverse probability weighting and weighted logistic regression, open repair 30 day mortality yielded an OR 1.9, 95% CI 1.2-3.1, p = .01 compared with EVAR. Factors independently associated with death included more proximal extent aneurysm (referent [ref]: juxtarenal: OR 2.0 per extent increase, 95% CI 1.4-3.0, p Conclusion The 30 day mortality was 4.6% for juxtarenal AAA, 9.5% for suprarenal AAA, and 14.7% for type IV TAAA. The open repair odds of 30 day mortality was nearly twice that of endovascular repair for cAAA. Independent associations with death included BMI

Multilayer bare stent technique in treating intact mycotic suprarenal aortic aneurysm: a case report.

BackgroundInvasive aspergillosis (IA) related mycotic aortic aneurysm is rare in immunocompetent patient. The endovascular therapy remains controversial due to potential risk of graft infection, while the suprarenal cases might face catastrophic complications during open surgery.Case summaryWe presented an IA case with suprarenal abdominal aortic aneurysm confirmed by joint effusion. Multilayer bare stent technique was performed to preserve visceral blood flow and promote aneurysmal thrombus formation, along with antifungal treatment. Two years of follow-up revealed complete aneurysm thrombosis without evidence of infection.DiscussionFungal infection that affects the aorta is difficult to recognize due to often negative blood cultures. Close observation is recommended in case of suspicion of mycotic aneurysms. Multilayer bare stent technique can restore luminal laminar blood flow and reduce the risk of infection in intact mycotic suprarenal aortic aneurysm.

Editor's Choice – Mortality is High Following Elective Open Repair of Complex Abdominal Aortic Aneurysms

To evaluate the 30 day mortality of elective open complex abdominal aortic aneurysm (cAAA) repair and identify factors associated with death. This was a retrospective cohort study using a Targeted Vascular Module from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP). All patients undergoing elective repair for juxta- and suprarenal abdominal aortic aneurysm (AAA), or type IV thoraco-abdominal aneurysms (TAAA) from 2011 to 2017 were identified. Thirty day mortality and complication rates for open repair were established. A comparison endovascular aneurysm repair (EVAR) group was extracted from the same time period, and inverse probability weighting was applied for comparison. Logistic regression was used to identify factors independently associated with open repair mortality. Of the 957 patients who underwent an elective open cAAA repair over the study period, 65 (6.8%) died. The mean age of the patient was 71.3±8.0 years. The distribution by aneurysm type was 605 juxtarenal AAA (28 deaths, 4.6%); 284 suprarenal AAA (16 deaths, 9.5%), and 68 type IV TAAA (10 deaths, 14.7%). During the same time period, there were 1149 endovascular repairs for cAAA, with 43 deaths (3.7%). After inverse probability weighting and weighted logistic regression, open repair 30 day mortality yielded an OR 1.9, 95% CI 1.2-3.1, p=.01 compared with EVAR. Factors independently associated with death included more proximal extent aneurysm (referent [ref]: juxtarenal: OR 2.0 per extent increase, 95% CI 1.4-3.0, p<.001), BMI<18.5 (OR 4.0, 95% CI 1.6-10.1, p=.003), history of severe chronic obstructive pulmonary disease (COPD) (OR 2.6, 95% CI 1.5-4.4, p=.001), more severe chronic kidney disease (CKD) (ref: none/mild): OR 1.9, 95% CI 1.2-2.8, p=.004), and age (OR 1.06/year, 95% CI 1.02-1.09, p=.002. The 30 day mortality was 4.6% for juxtarenal AAA, 9.5% for suprarenal AAA, and 14.7% for type IV TAAA. The open repair odds of 30 day mortality was nearly twice that of endovascular repair for cAAA. Independent associations with death included BMI <18.5, more severe CKD level, more proximally extending aneurysm, age, and history of advanced COPD.

Evolving Utility of Endovascular Treatment of Juxtarenal, Pararenal, and Suprarenal Abdominal Aortic Aneurysms Associated With Increased Risk of Mortality Over Time

Continued advances in endovascular technologies are resulting in fewer open abdominal aortic aneurysm (AAA) repairs. In addition, more complex juxtarenal, pararenal, and suprarenal (JPS) AAAs are being managed with various endovascular techniques. This study sought to evaluate the evolving trends in endovascular aneurysm repair (EVAR) of AAAs, hypothesizing increased rate of JPS AAA repair by EVAR. We also sought to evaluate the risk for morbidity and mortality for EVAR and open aneurysm repair (OAR) of JPS AAAs over time. The 2011-2017 American College of Surgeons National Surgical Quality Improvement Program Procedure-Targeted Vascular database was queried for patients undergoing OAR or EVAR for AAAs. A multivariable logistic regression analysis was performed for both infrarenal and JPS AAA repairs. Of 18,661 patients who underwent AAA repair, 3,941 (21.1%) were OAR and 14,720 (78.9%) were EVAR. The rate of OAR decreased from 29.5% in 2011 to 21.3% in 2017 (P<0.001) with a geometric-mean-annual decrease of 27.8%. The rate of EVAR increased from 70.5% to 78.7% during the same time period (P<0.001) with a geometric-mean-annual increase of 11.6%. These trends remained true for both infrarenal and JPS AAAs. After adjusting for covariates, there was no difference in associated risk of 30-day mortality, renal complications, or ischemic colitis for either OAR or EVAR over each incremental year for infrarenal AAAs (P>0.05). However, in patients undergoing EVAR for JPS AAAs, the associated risk of mortality increased with each incremental year (odds ratio [OR]: 1.30, confidence interval [CI]: 1.01-1.69, P=0.039), whereas there was no difference in the risk of mortality for OAR of JPS AAAs with each incremental year (OR: 1.11, CI: 0.99-1.23, P=0.067). The rate of OAR for AAA has decreased over the past seven years with an increase in EVAR, particularly for more complex JPS AAAs. The associated risk for morbidity and mortality for treatment of infrarenal AAAs was not significantly affected by this increased utility of EVAR. The associated risk of mortality for JPS AAAs treated by EVAR increased over time, whereas this trend for associated risk of mortality was not seen for OAR of JPS AAAs. These findings, especially the increased associated risk of mortality over time with EVAR for JPS AAAs, warrant careful prospective analysis.

Effect of Chronic Kidney Disease on 30-Day Outcomes for Repair of Complex Abdominal Aortic Aneurysm

Chronic kidney disease (CKD) has been shown to increase morbidity and mortality after repair of infrarenal abdominal aortic aneurysm (AAA) and has a negative impact on long-term survival of patients undergoing aneurysm repair. This study further analyzes the association of CKD severity with the perioperative outcomes of open aortic repair (OAR) and fenestrated endovascular aneurysm repair (FEVAR) of complex AAA (cAAA; juxtarenal, suprarenal, and supravisceral AAAs).

Contemporary mortality after emergent open repair of complex abdominal aortic aneurysms

ObjectiveMortality after open repair for emergent complex abdominal aortic aneurysm (AAA) is poorly defined. This study evaluated the 30-day mortality of open complex AAA repair performed for rupture or other emergent indication using a national surgical registry. We subsequently identified factors associated with mortality. MethodsThe targeted vascular module from the American College of Surgeons National Surgical Quality Improvement Program was queried to identify patients undergoing open repair for juxtarenal and suprarenal AAAs or type IV thoracoabdominal aneurysms (TAAAs) for rupture or other emergent indication from 2011 to 2017. Univariate analyses were performed using the Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. Multivariable logistic regression was performed to identify factors independently associated with mortality. ResultsWe included 374 patients who underwent an emergent complex open AAA repair during the study period. There were 142 (38%) cases performed for rupture with hypotension, 141 (38%) for rupture without hypotension, 40 (11%) for symptomatic AAA, and 51 (14%) for another indication. The distribution by aneurysm type was 224 juxtarenal AAAs, 122 suprarenal AAAs, and 28 type IV TAAAs. Overall, there was a 30-day mortality of 32% (118 deaths). For those with juxtarenal AAA repair, 67 (30%) patients died within 30 days; there were 38 (31%) deaths within 30 days in those with suprarenal AAA, and 13 (46%) deaths within 30 days in those with type IV TAAA. On univariate analysis, preoperative variables associated with death were increasing age, use of a transperitoneal surgical approach, lower preoperative estimated glomerular filtration rate, low baseline albumin concentration (<3.5 g/dL), need for preoperative transfusion, low body mass index (<18.5 kg/m2), and hypotension at presentation. Intraoperative variables associated with mortality were supraceliac clamp location and concurrent renal revascularization. On multivariable analysis, factors independently associated with death included rupture with associated hypotension (reference: other emergent indication; adjusted odds ratio [AOR], 3.28; confidence interval [CI], 1.75-5.41; P < .001), age >60 years (reference: <60 years; AOR, 1.59; CI, 1.18-2.13; P = .002), longitudinal laparotomy incision (reference: retroperitoneal; AOR, 3.28; CI, 1.75-6.16; P < .001), and supraceliac cross-clamp (reference: clamp above one renal artery; AOR, 2.14; CI, 1.31-3.50; P = .003). ConclusionsNearly one-third of patients die within 30 days of emergent open complex AAA repair. Mortality is particularly high for patients with type IV TAAAs, approaching 50%. Predictors of 30-day mortality include rupture with associated hypotension, increasing age, supraceliac clamp location, and longitudinal transperitoneal repair approach. These results will help inform surgical decisions preoperatively and intraoperatively.

Outcomes after treatment of complex aortic abdominal aneurysms with the fenestrated Anaconda endograft

ObjectiveTo date, information on the fenestrated Anaconda endograft is limited to case series with a small sample size. This study was performed to assess the technical and clinical outcome of this device in a large international case series. MethodsAll worldwide centers having treated more than 15 complex abdominal aortic aneurysms (AAA) or type IV thoracoabdominal aortic aneurysm patients with the fenestrated Anaconda endograft were approached. Main outcome parameters were procedural technical success, postoperative and follow-up clinical outcome for endoleaks, target vessel patency, reintervention rate, and patient survival. ResultsThree hundred thirty-five consecutive cases treated between June 2010 and May 2018 in 11 sites were included. Patients were treated for a short neck infrarenal (n = 98), juxtarenal (n = 191), suprarenal AAA (n = 27), or type IV thoracoabdominal aortic aneurysm (n = 19). Mean age was 73.6 ± 4.6 years (292 male). Endografts contained a total of 920 fenestrations, with a mean of 2.7 ± 0.8 fenestrations per case. Technical success was 88.4% (primary, 82.7%; assisted primary 5.7%). In 6.9% of cases, a procedural type IA endoleak was observed, spontaneously disappearing in 82.6% during early follow-up. The development of a type IA endoleak was associated with greater neck angulation (odds ratio [OR], 0.94; P = .01), three fenestrations (OR, 42.7; P = .01) and the presence of augmented proximal rings (OR, 0.17; P = .03). Median follow-up was 1.2 years (interquartile range, 0.4-2.6). The mean estimated glomerular filtration rate deteriorated from 67.6 ± 19.3 mL/min/1.73 m2 preoperatively to 59.3 ± 22.7 mL/min/1.73 m2 at latest follow-up (P = .00). The freedom from AAA growth were 97.9 ± 0.9% (n = 190) and 86.4 ± 3.0% (n = 68), with a freedom from AAA rupture of 99.7 ± 0.3% (n = 191) and 99.1 ± 0.7% (n = 68), at 1 and 3 years, respectively. The endoleak-free survival, excluding spontaneously resolved procedural endoleaks, at 1 and 3 years was 73.4 ± 2.6 (n = 143) and 65.6 ± 3.4% (n = 45), respectively. The target vessel patency at one and three years were 96.4 ± 0.7% (n = 493) and 92.7 ± 1.4% (n = 156), respectively. A total of 75 reinterventions were done in 64 cases (19.1%), of which 25 cases for an endoleak. The reintervention-free survival at 1 and 3 years were 83.6 ± 2.2% (n = 190) and 71.0 ± 3.7% (n = 68), respectively. No deaths during procedure, extending within 24 hours postoperatively, were observed. Within 30 days 14 patients (4.2%) died and during follow-up another 39 patients (11.6%) died. Three deaths were considered AAA related (one rupture, one endograft infection, and one bilateral renal artery occlusion). The estimated cumulative survival at 1 and 3 years were 89.8 ± 1.8% (n = 191) and 79.2 ± 3.0% (n = 68), respectively. ConclusionsThe custom-made fenestrated Anaconda endograft is a valuable option for the treatment of a complex AAA. A procedural type IA endoleak is seen relatively frequently, but spontaneously resolves in most cases.

Risk Factors of Postoperative Intestinal Ischemia After Abdominal Aortic Aneurysm Repair

Introduction - Intestinal ischemia remains a complication following abdominal aortic aneurysm (AAA) repair associated with a high mortality.1-6 The influence of possible risk factors for developing postoperative intestinal ischemia needs clarification. We sought to define predictors as well as the related mortality and to form a prediction model with the predictiors found. Methods - A nationwide population-based cohort study of 9433 patients who underwent an AAA operation between 2014 and 2016 was conducted. Potential risk factors were determined by reviewing prior studies and univariate analysis. With logistic regression analysis independent predictors of intestinal ischemia were established. These variables were used to form a prediction model. Results - Intestinal ischemia occurred in 267 patients (2.8%). Rupture of AAA was the most important predictor of developing intestinal ischemia (odds ratio [OR], 5.9, 95% confidence interval [CI]4.4-8.0), followed by having a suprarenal AAA (OR 3.4; CI 1.1-10.6). Associated procedural factors were open repair (OR 2.8; 95%CI 1.9-4.2), blood loss >1L (OR 3.6; 95%CI 1.7-7.5) and prolonged operating time (OR 2.0; 95%CI 1.4-2.8). Patient characteristics included having peripheral arterial disease (OR 2.4; 95%CI 1.3-4.4), female gender (OR 1.7; 95%CI 1.2-2.4), renal insufficiency (OR 1.7; 1.3-2.2) and pulmonary history (OR 1.6; 95%CI 1.2-2.2). Age <68 proved to be a protective factor (OR 0.5; 95%CI 0.4-0.8). Associated mortality was higher in patients with intestinal ischemia versus patients without (50.6% vs 5.1%, p<.001). A prediction model with an excellent AUC=0.878 (95% CI 0.860-0.896) could be formed. Conclusion - The prediction model can be used to identify patients at high risk for developing intestinal ischemia and possibly lower the mortality risk.